DocDollars

Pacira Pharmaceuticals Incorporated

NJ · United States · Reporting entity ID 100000000135

Total reported 2019–2025
$54.3M
#165 of 2,960 reporting companies — 0.1% of all reported industry payments
$36.1M in general payments across 98,077 records, plus $18.2M in research funding across 1,142 records.

How it breaks down

General payments $36,061,598
Research funding $18,198,633

Where this comes from

Figures are from the CMS Open Payments “payments grouped by reporting entity” dataset, queried live. Reporting entities are applicable manufacturers and group purchasing organisations required to report under the Sunshine Act.

Summary

Pacira Pharmaceuticals Incorporated reported $54.3M to US doctors and teaching hospitals from 2019 to 2025, ranking #165 of 2,960 reporting companies. 34% of that was research funding and 66% general payments such as consulting, speaking, food and travel. 98,077 general payment records and 1,142 research records were filed.

Common questions about Pacira Pharmaceuticals Incorporated

How much has Pacira Pharmaceuticals Incorporated paid US doctors?

Pacira Pharmaceuticals Incorporated reported $54,260,231 to US physicians and teaching hospitals across the 2019–2025 Open Payments program years: $36,061,598 in general payments, $18,198,633 in research funding.

How does Pacira Pharmaceuticals Incorporated rank among drug and device companies?

It ranks #165 of 2,960 reporting entities by total reported value, about 0.1% of all industry payments in the dataset.

Does a payment from Pacira Pharmaceuticals Incorporated mean a doctor did something wrong?

No. Open Payments records transfers of value such as speaking fees, consulting, meals, travel and research funding. The data shows the relationship, not its effect on prescribing or care.